Meek Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.50 Cr
as on 24-10-2024
- Paid Up Capital ₹ 2.17 Cr
as on 24-10-2024
- Company Age 19 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 2.45 Cr
as on 24-10-2024
- Revenue -3.19%
(FY 2023)
- Profit -315.26%
(FY 2023)
- Ebitda -109.78%
(FY 2023)
- Net Worth -8.75%
(FY 2023)
- Total Assets -5.89%
(FY 2023)
About Meek Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 Cr and a paid-up capital of Rs 2.17 Cr.
The company has closed loans amounting to ₹2.45 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Ankur Agarwal, Deepak Agarwal, Ashok Agarwal, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24230UR2005PTC000876
- Company No.
000876
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Aug 2005
- Date of AGM
07 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Uttarakhand
Industry
Company Details
- Location
Udham Singh Nagar, Uttarakhand, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Meek Pharma Private Limited offer?
Meek Pharma Private Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, Antibiotic Injection, Common Disease Medicines, Antihistamines.
Who are the key members and board of directors at Meek Pharma?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ankur Agarwal  | Director | 07-Oct-2006 | Current |
| Deepak Agarwal | Director | 22-Aug-2005 | Current |
| Ashok Agarwal | Director | 22-Aug-2005 | Current |
| Anshul Agarwal | Additional Director | 09-Aug-2024 | Current |
| Sachin Agrawal | Additional Director | 09-Aug-2024 | Current |
Financial Performance and Corporate Structure Insights of Meek Pharma.
Meek Pharma Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 3.19% decrease. The company also saw a substantial fall in profitability, with a 315.26% decrease in profit. The company's net worth dipped by a decrease of 8.75%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Meek Pharma?
In 2023, Meek Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Safecon Lifesciences Private LimitedActive 8 years 7 monthsAshok Agarwal and Anshul Agarwal are mutual person
Wellcon Animal Health Private LimitedActive 9 years 11 monthsAnkur Agarwal and Ashok Agarwal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Central Bank Of India Creation Date: 04 May 2007 | ₹1.70 Cr | Satisfied |
Bank Of Baroda Creation Date: 17 Aug 2006 | ₹7.50 M | Satisfied |
How Many Employees Work at Meek Pharma?
Meek Pharma has a workforce of 67 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Meek Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Meek Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
